How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,859 results for

Hyperpigmentation

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Postinflammatory Hyperpigmentation (Diagnosis)

Postinflammatory Hyperpigmentation (Diagnosis) Postinflammatory Hyperpigmentation: Background, Pathophysiology, Etiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTA2OTE5MS1vdmVydmlldw== processing (...) > Postinflammatory Hyperpigmentation Updated: May 04, 2018 Author: Robert A Schwartz, MD, MPH; Chief Editor: Dirk M Elston, MD Share Email Print Feedback Close Sections Sections Postinflammatory Hyperpigmentation Overview Background Postinflammatory hyperpigmentation (PIH) is a frequently encountered problem and represents the sequelae of various cutaneous disorders as well as therapeutic interventions. [ ] This acquired excess of pigment can be attributed to various preceding disease processes that affect

2014 eMedicine.com

142. Secondary hyperpigmentation during interferon alfa treatment for chronic hepatitis C virus infection. (PubMed)

Secondary hyperpigmentation during interferon alfa treatment for chronic hepatitis C virus infection. Interferon alfa remains the central treatment for chronic hepatitis C virus (HCV) infection. Cases of cutaneous and mucous hyperpigmentations during interferon alfa treatment have been reported, but they are considered rare adverse effects.To study the clinical presentation and frequency of hyperpigmentation in patients receiving interferon alfa treatment for chronic HCV infection.Prospective (...) with hyperpigmentation. Hyperpigmentation of the oral mucous membrane, acquired longitudinal melononychia, and hyperpigmentation of the face were each observed in 7 patients (9%). All patients with hyperpigmentation of the skin had skin type III or IV and worked outside without sun protection. The intensity of pigmentation was reported to decrease progressively when interferon treatment was discontinued. Most patients with hyperpigmentation of the oral mucosa also had melanonychia. However, patients

Full Text available with Trip Pro

2013 JAMA dermatology (Chicago, Ill.)

143. Mixed hyperpigmentation and hypopigmentation of iris and choroid in Chediak-Higashi syndrome. (PubMed)

Mixed hyperpigmentation and hypopigmentation of iris and choroid in Chediak-Higashi syndrome. An 8-year-old Taiwanese girl presented with hyperpigmentation and scattered hypopigmentation in her irides and choroids. Her skin showed hyperpigmentation with speckled hypopigmentation over cheeks and sun-exposed areas. Medical history was remarkable for frequent infectious episodes and lower extremity bruising. A peripheral blood smear revealed large inclusion bodies in the cytoplasm of neutrophils

2013 JAAPOS - Journal of the American Association for Pediatric Ophthalmology and Strabismus

144. Pain and Hyperpigmentation of the Toes: A Quiz. (PubMed)

Pain and Hyperpigmentation of the Toes: A Quiz. 23756605 2014 09 11 2014 02 26 1651-2057 94 2 2014 Mar Acta dermato-venereologica Acta Derm. Venereol. Pain and hyperpigmentation of the toes: a quiz. Hyperpigmentation of the toes caused by millipedes. 253-4 10.2340/00015555-1645 Sampaio Felipe Maurício Soeiro FM Department of Dermatology, Oswaldo Cruz Foudation, 21940210 Rio de Janeiro, Brazil. felipemauricio@uol.com.br. Valviesse Vitor Ribeiro Gomes de Almeida VR Lyra-da-Silva Julia Ocampo JO (...) Mesquita Emerson Cicilini EC Brandão Luciana Gomes Pedro LG do Valle Antonio Carlos Francesconi AC eng Case Reports Journal Article Sweden Acta Derm Venereol 0370310 0001-5555 IM Animals Arthropods Bites and Stings complications Brazil Female Humans Hyperpigmentation etiology Pain etiology Toes Young Adult 2013 6 13 6 0 2013 6 13 6 0 2014 9 12 6 0 ppublish 23756605 10.2340/00015555-1645

Full Text available with Trip Pro

2013 Acta Dermato-Venereologica

145. A Novel Germline KIT Mutation (p.L576P) in a Family Presenting With Juvenile Onset of Multiple Gastrointestinal Stromal Tumors, Skin Hyperpigmentations, and Esophageal Stenosis. (PubMed)

A Novel Germline KIT Mutation (p.L576P) in a Family Presenting With Juvenile Onset of Multiple Gastrointestinal Stromal Tumors, Skin Hyperpigmentations, and Esophageal Stenosis. Familial gastrointestinal stromal tumor (GIST) syndrome is a rare autosomal dominant genetic disorder. We report on a kindred in which 3 family members carry a germline mutation (c.1727T>C, p.L576P) in exon 11 of the KIT gene. This mutation was not reported so far in familial GISTs. Apart from multiple GISTs in 2

2013 American Journal of Surgical Pathology

146. Facial hyperpigmentation: causes and treatment. (PubMed)

Facial hyperpigmentation: causes and treatment. By midcentury, the U.S.A. will be more ethnically and racially diverse. Skin of colour will soon constitute nearly one-half of the U.S. population, and a full understanding of skin conditions that affect this group is of great importance. Structural and functional differences in the skin, as well as the influence of cultural practices, produce variances in skin disease and presentation based on skin type. In the skin of colour population (...) , dyschromia is a growing concern, and a top chief complaint when patients present to the physician. A thorough understanding of the aetiology and management strategies of facial hyperpigmentation is of importance in caring for those afflicted and also in the development of new therapies. © 2013 The Authors BJD © 2013 British Association of Dermatologists.

Full Text available with Trip Pro

2013 British Journal of Dermatology

147. Hyperpigmentation: types, diagnostics and targeted treatment options. (PubMed)

Hyperpigmentation: types, diagnostics and targeted treatment options. Pigment formation is highly complex. It is involved in inflammation, sun protection and many other processes. For practical purposes, such as exposure time for sun tanning, six skin types are distinguished according to Fitzpatrick, listed in decreasing lightness. The hyperpigmentation commonly occurs in Fitzpatrick skin types III to VI and can have a considerable impact on quality of life.In this article we will give

Full Text available with Trip Pro

2013 Journal of the European Academy of Dermatology and Venereology

148. A focused review on acne-induced and aesthetic procedure-related postinflammatory hyperpigmentation in Asians. (PubMed)

A focused review on acne-induced and aesthetic procedure-related postinflammatory hyperpigmentation in Asians. Postinflammatory hyperpigmentation (PIH) is a common consequence following cutaneous inflammation in dark-skinned individuals with Fitzpatrick skin phototypes (SPTs) III-VI. The exact pathogenesis of this condition is unknown, but is believed to be an integral part of the normal response of the skin to inflammatory stimuli. PIH can last from months to years and may significantly impair

Full Text available with Trip Pro

2013 Journal of the European Academy of Dermatology and Venereology

149. 4-n-butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation. (PubMed)

4-n-butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation. Hyperpigmentary disorders like melasma, actinic and senile lentigines are a major cosmetic concern. Therefore, many topical products are available, containing various active ingredients aiming to reduce melanin production and distribution. The most prominent target for inhibitors of hyperpigmentation is tyrosinase, the key regulator of melanin production. Many inhibitors of tyrosinase (...) , 4-n-butylresorcinol reduced visibly the appearance of age spots, while the control spots showed no improvement. A second study showed that 4-butylresorcinol was more effective than 4-hexylresorcinol and 4-phenylethylresorcinol.The present in vitro and in vivo data prove the high inhibitory capacity of 4-n-butylresorcinol on human tyrosinase activity, exceeding by far the potency of hydroquinone, arbutin and kojic acid. The resulting clinical improvement of skin hyperpigmentations reveals 4-n

Full Text available with Trip Pro

2013 Journal of the European Academy of Dermatology and Venereology

150. Efficacy and Safety of Biocellulose Sheet Containing Anti-hyperpigmentation Agent ("Biocellulose Mask", "Farhorm®") in Patients Receiving Laser Treatment

Efficacy and Safety of Biocellulose Sheet Containing Anti-hyperpigmentation Agent ("Biocellulose Mask", "Farhorm®") in Patients Receiving Laser Treatment Efficacy and Safety of Biocellulose Sheet Containing Anti-hyperpigmentation Agent ("Biocellulose Mask", "Farhorm®") in Patients Receiving Laser Treatment - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail (...) Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy and Safety of Biocellulose Sheet Containing Anti-hyperpigmentation Agent ("Biocellulose Mask", "Farhorm®") in Patients Receiving Laser Treatment The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government

2013 Clinical Trials

151. Diltiazem-Associated Hyperpigmentation (PubMed)

Diltiazem-Associated Hyperpigmentation 23846341 2014 08 12 2018 11 13 1525-1497 28 12 2013 Dec Journal of general internal medicine J Gen Intern Med Diltiazem-associated hyperpigmentation. 1676 10.1007/s11606-013-2530-1 Campbell Michelle M Wayne State University School of Medicine, Detroit, MI, USA. Ahluwalia Jesleen J Watson Alice C AC eng Case Reports Journal Article 2013 07 12 United States J Gen Intern Med 8605834 0884-8734 0 Antihypertensive Agents EE92BBP03H Diltiazem IM Antihypertensive (...) Agents adverse effects Diltiazem adverse effects Female Humans Hyperpigmentation chemically induced diagnosis Middle Aged 2012 11 15 2013 06 10 2013 01 31 2013 7 13 6 0 2013 7 13 6 0 2014 8 13 6 0 ppublish 23846341 10.1007/s11606-013-2530-1 PMC3832732 J Dermatol. 2010 Sep;37(9):807-11 20883365 Dermatol Online J. 2011;17(7):14 21810399 Cutis. 2010 Aug;86(2):82-4 20919601

Full Text available with Trip Pro

2013 Journal of General Internal Medicine

152. Generalized hyperpigmentation in Wilson's disease: An unusual association (PubMed)

Generalized hyperpigmentation in Wilson's disease: An unusual association Wilson's disease, an autosomal recessive disorder of copper metabolism, most commonly presents either with hepatic or neurological features. But, it may sometimes have certain atypical presentations posing diagnostic difficulties. We report here a case of Wilson's disease presenting with generalized hyperpigmentation of skin who also developed neurological manifestations subsequently. We aim to highlight the importance (...) of keeping Wilson's disease as one of the differentials in patients who present with hyperpigmentation and neurological symptoms compatible with copper deposits in the central nervous system and proceed for investigations accordingly.

Full Text available with Trip Pro

2013 Journal of neurosciences in rural practice

153. Tolerance and efficacy of a product containing ellagic and salicylic acids in reducing hyperpigmentation and dark spots in comparison with 4% hydroquinone. (PubMed)

Tolerance and efficacy of a product containing ellagic and salicylic acids in reducing hyperpigmentation and dark spots in comparison with 4% hydroquinone. Hydroquinone (HQ) is the benchmark prescription agent for skin lightening. However, HQ use is recently banned in Europe and in parts of Asia because of potential long-term consequences, including carcinogenesis when orally consumed. This has resulted in development of alternative skin-lightening agents with comparable efficacy to HQ

2013 Journal of drugs in dermatology : JDD Controlled trial quality: uncertain

154. Topical niacinamide 4% and desonide 0.05% for treatment of axillary hyperpigmentation: a randomized, double-blind, placebo-controlled study. (PubMed)

Topical niacinamide 4% and desonide 0.05% for treatment of axillary hyperpigmentation: a randomized, double-blind, placebo-controlled study. Axillary hyperpigmentation is a frequent cause of cosmetic consultations in dark-skinned women from tropical areas, including Latin America. Currently, there is no widely accepted treatment for the disorder, but it is usually treated with bleaching agents because it is considered a variant of inflammatory hyperpigmentation. The purpose of this study (...) was performed by histochemistry and immunohistochemistry, assisted by computerized morphometric analysis.Both niacinamide and desonide induced significant colorimetric improvement compared with placebo; however, desonide showed a better depigmenting effect than niacinamide. A good to excellent response was achieved in 24% of cases for niacinamide, 30% for desonide, and 6% for placebo. We observed a marked disruption of the basal membrane in axillary hyperpigmentation and an inflammatory infiltrate

Full Text available with Trip Pro

2013 Clinical, cosmetic and investigational dermatology Controlled trial quality: uncertain

155. Evaluation of a hydroquinone-free skin brightening product using in vitro inhibition of melanogenesis and clinical reduction of ultraviolet-induced hyperpigmentation.

Evaluation of a hydroquinone-free skin brightening product using in vitro inhibition of melanogenesis and clinical reduction of ultraviolet-induced hyperpigmentation. Skin lightening preparations are used by people all over the world for a diverse range of dermatologic indications. Hydroquinone (HQ) is the gold standard and remains the only prescription product available in the United States for the treatment of generalized facial hyperpigmentation. Irritation and the risk of exogenous (...) and distribution. A single-center, double-blind comparison clinical study of 18 subjects was conducted to evaluate the efficacy of the product in reducing ultraviolet-induced hyperpigmentation. Test sites were irradiated with 1.0, 1.5, 2.0, and 2.5 minimal erythema doses. After 5 days, to allow for pigmentation development, the product or 4% HQ cream was applied to the respective test sites, once daily for 4 weeks. Chroma Meter measurements (L* brightness) and standardized digital photographs were taken

2013 Journal of drugs in dermatology : JDD

156. Cyclophosphamide-induced nail hyperpigmentation in a child (PubMed)

Cyclophosphamide-induced nail hyperpigmentation in a child 22787324 2012 10 02 2018 11 13 1998-3662 22 2 2012 Mar Indian journal of nephrology Indian J Nephrol Cyclophosphamide-induced nail hyperpigmentation in a child. 149 10.4103/0971-4065.97144 Saha A A Department of Pediatrics, Division of Pediatric Nephrology, PGIMER and Associated Dr. RML Hospital, New Delhi, India. Arora N N Mehra N N Dubey N K NK eng Journal Article India Indian J Nephrol 8914356 0971-4065 2012 7 13 6 0 2012 7 13 6 0

Full Text available with Trip Pro

2012 Indian Journal of Nephrology

157. Triple Combination and Glycolic Peels in Post-Acne Hyperpigmentation (PubMed)

Triple Combination and Glycolic Peels in Post-Acne Hyperpigmentation 22557866 2012 05 31 2018 11 13 0974-5157 5 1 2012 Jan Journal of cutaneous and aesthetic surgery J Cutan Aesthet Surg Triple combination and glycolic peels in post-acne hyperpigmentation. 60-1 10.4103/0974-2077.94335 Godse Kiran K Sakhia Jagdish J eng Letter India J Cutan Aesthet Surg 101525405 0974-2077 2012 5 5 6 0 2012 5 5 6 0 2012 5 5 6 1 ppublish 22557866 10.4103/0974-2077.94335 JCAS-5-60 PMC3339139 J Eur Acad Dermatol

Full Text available with Trip Pro

2012 Journal of cutaneous and aesthetic surgery

158. Postinflammatory Hyperpigmentation After Skin Prick Testing (PubMed)

Postinflammatory Hyperpigmentation After Skin Prick Testing 23268476 2012 12 27 2019 02 11 1939-4551 5 5 2012 May The World Allergy Organization journal World Allergy Organ J Postinflammatory hyperpigmentation after skin prick testing. 57-8 10.1097/WOX.0b013e3182488069 Ludman Sian S Department of MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, Division of Asthma, Allergy and Lung Biology, King's College London, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom. Penagos

Full Text available with Trip Pro

2012 The World Allergy Organization journal

159. Synergistic Combination of an In-office Procedure and Home Regimen for the Treatment of Facial Hyperpigmentation (PubMed)

Synergistic Combination of an In-office Procedure and Home Regimen for the Treatment of Facial Hyperpigmentation Hyperpigmentation disorders, such as melasma and solar lentigines, pose a significant treatment challenge for most patients. Combining a series of in-office procedures, such as chemical peels and light- and laser-based treatments, with maintenance therapies have been shown to provide greater efficacy than one treatment alone. However, receiving multiple in-office procedures may (...) . Physician-graded overall improvement in hyperpigmentation, standardized photography, and patient satisfaction were evaluated at Weeks 4, 8, and 12. At Week 12, all eight patients demonstrated improvements of at least 25 percent in overall facial hyperpigmentation, with six of the patients demonstrating a 50- or 75-percent overall improvement. One hundred percent of the patients rated their experience with the novel treatment regimen as "excellent" or "good" reflecting high patient satisfaction

Full Text available with Trip Pro

2012 The Journal of clinical and aesthetic dermatology

160. Minocycline Hyperpigmentation (PubMed)

Minocycline Hyperpigmentation 22560532 2012 07 03 2013 12 13 1942-5546 87 5 2012 May Mayo Clinic proceedings Mayo Clin. Proc. Minocycline hyperpigmentation. e33 10.1016/j.mayocp.2012.02.013 Wetter David A DA Department of Dermatology, Mayo Clinic, Rochester, MN, USA. eng Case Reports Journal Article England Mayo Clin Proc 0405543 0025-6196 0 Anti-Bacterial Agents FYY3R43WGO Minocycline AIM IM Aged Anti-Bacterial Agents administration & dosage adverse effects Arthritis, Rheumatoid drug therapy (...) Humans Hyperpigmentation chemically induced diagnosis Male Minocycline administration & dosage adverse effects Risk Factors Skin drug effects 2012 02 27 2012 02 27 2012 5 8 6 0 2012 5 9 6 0 2012 7 4 6 0 ppublish 22560532 S0025-6196(12)00308-4 10.1016/j.mayocp.2012.02.013 PMC3498181

Full Text available with Trip Pro

2012 Mayo Clinic Proceedings

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>